|
Video: What is a Stock Split?
|
|
Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer. According to our ALDX split history records, Aldeyra Therapeutics has had 0 splits. | |
|
Aldeyra Therapeutics (ALDX) has 0 splits in our ALDX split history database.
Looking at the ALDX split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aldeyra Therapeutics shares, starting with a $10,000 purchase of ALDX, presented on a split-history-adjusted basis factoring in the complete ALDX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/06/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$6.10 |
|
End price/share: |
$3.27 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-46.39% |
|
Average Annual Total Return: |
-6.10% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,362.31 |
|
Years: |
9.90 |
|
|
|
|
|